The University of Michigan (UM) Prostate SPORE Administration Gore is responsible for leadership, guidance and management. The Administration Gore oversees all aspects and performs numerous duties across the expansive scope of the SPORE to support the translational goals of the investigators. The SPORE Administration Gore is guided by the following Specific Aims:
Specific Aim 1 : Provide scientific, programmatic and administrative leadership to all aspects of the SPORE.
Specific Aim 2 : Develop, facilitate and monitor progress of translational aims with project co-leaders. The Clinical Applications Committee, the annual review with the External Advisory Board and Steer Committee and the monthly meetings between project leaders and the SPORE PI all function to maintain a robust SPORE infrastructure and facilitate the progress of translational objectives.
Specific Aim 3 : Identify, support, and facilitate scientific collaborations. The Administration Core is charged with creating a culture of collaboration through fostering and helping to establish and maintain successful collaborations.
Specific Aim 4 : Facilitate communication between investigators and groups within the Prostate SPORE as well as with other UM SPOREs, the SPORE network outside UM, NCI and investigators across the spectrum of translational cancer research.
Specific Aim 5 : Perform fiscal and data management functions.
Specific Aim 6 : Coordinate patient advocacy and provide functional and ethical oversight to projects and cores. The Gore provides support and oversight to ensure that all investigators have IRB and animal approvals in place to conduct research. The Gore will develop and maintain an advocacy portal to prostate cancer patient community. Arul M. Chinnaiyan, MD, PhD, serves as principal investigator of the Administrative Core and provides overall scientific oversight. Kathleen Cooney, MD, continues to serve as a co-director to oversee all of the developmental programs, patient advocacy efforts, as well as the Biostatistics and Tissue Gores. Ganesh Palapattu, M.D., serves as a co-director responsible for the translational science of the UM Prostate SPORE as Director of the Clinical Applications Committee. Ms. Jill Miller has served as UM Prostate SPORE administrator since 1998 and will continue in this role. This core provides the framework to support the success and mission of the UM Prostate SPORE as a cohesive group of investigators committed to supporting translational research in prostate cancer.
The goals of the UMCCC Prostate SPORE are to foster research productivity, promote interaction and collaboration and optimize the institution's strengths and unique scientific opportunities to advance prostate cancer prevention, diagnosis, treatment and survivorship.
|Zhang, Yajia; Pitchiaya, Sethuramasundaram; Cie?lik, Marcin et al. (2018) Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet 50:814-824|
|Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999|
|Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:|
|Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :|
|Niknafs, Yashar S; Pandian, Balaji; Gajjar, Tilak et al. (2018) MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data. Neoplasia 20:1144-1149|
|Xiao, Lanbo; Tien, Jean C; Vo, Josh et al. (2018) Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Cancer Res 78:5731-5740|
|Piert, Morand; Shankar, Prasad R; Montgomery, Jeffrey et al. (2018) Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications. EJNMMI Res 8:23|
|Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14|
|Rice, John D; Tsodikov, Alex (2017) Semiparametric profile likelihood estimation for continuous outcomes with excess zeros in a random-threshold damage-resistance model. Stat Med 36:1924-1935|
|Shen, Rex; Luo, Lan; Jiang, Hui (2017) Identification of gene pairs through penalized regression subject to constraints. BMC Bioinformatics 18:466|
Showing the most recent 10 out of 65 publications